BioSpace News Archive

Sanger sequencing is one of the oldest DNA sequencing methods carried out using oligonucleotide primers and chain termination.

According to Emergen Research, the global nanorobotics market size was USD 6.12 billion in 2020 and is expected to reach USD 14.03 billion in 2028 and register a revenue CAGR of 10.9% during the forecast period, 2021-2028.

Rising prevalence of infectious diseases, increasing investments in R&D activities, and growing application of antibiotics in development of bacterial and viral vaccines are key factors expected to drive market revenue growth.

The industry analysis report is considered a valuable source of information about the global Chronic Obstructive Pulmonary Disease Devices industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, announced it has granted inducement awards to new employees.

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of inducement awards to Brian Robinson, its new Senior Vice President, Global Medical Affairs.

Movano Inc. (NASDAQ:MOVE), a purpose-driven healthcare solutions company at the intersection of medtech and consumer devices, today announced that it will report first quarter 2022 financial and operating results on Thursday, May 12, 2022.

Iovance Biotherapeutics, Inc. announced that on April 21, 2022, the Company approved the grant of inducement stock options covering an aggregate of 323,675 shares of Iovance’s common stock to 34 new non-executive employees.

Statera Biopharma announced the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC on April 19, 2022 indicating that, because the Company has not yet filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, the Company does not comply with Nasdaq Listing Rule 5250 for continued listing.

CureVac N.V. will report financial results, and provide business updates for the fourth quarter and full-year 2021 on Thursday, April 28, 2022.